BIM
CLDX icon

BlackRock Investment Management’s Celldex Therapeutics CLDX Stock Holding History

BlackRock Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.45M Sell
27,253
-299
-1% -$17K ﹤0.01% 2444
2016
Q3 		$1.67M Sell
27,552
-196
-0.7% -$12.2K ﹤0.01% 2301
2016
Q2 		$1.83M Buy
27,748
+4,739
+21% +$301K ﹤0.01% 2177
2016
Q1 		$1.3M Buy
23,009
+801
+4% +$90.1K ﹤0.01% 2305
2015
Q4 		$5.22M Buy
22,208
+96
+0.4% +$20.9K 0.01% 1365
2015
Q3 		$3.5M Sell
22,112
-1,225
-5% -$347K ﹤0.01% 1636
2015
Q2 		$8.83M Buy
23,337
+3,669
+19% +$1.46M 0.01% 1081
2015
Q1 		$8.22M Buy
19,668
+1,825
+10% +$653K 0.01% 1063
2014
Q4 		$4.88M Sell
17,843
-184
-1% -$45.7K 0.01% 1374
2014
Q3 		$3.5M Buy
18,027
+68
+0.4% +$14.8K ﹤0.01% 1600
2014
Q2 		$4.4M Buy
17,959
+1,296
+8% +$293K 0.01% 1489
2014
Q1 		$4.42M Buy
16,663
+117
+0.7% +$44.8K 0.01% 1458
2013
Q4 		$6.01M Buy
16,546
+1,135
+7% +$437K 0.01% 1224
2013
Q3 		$8.19M Buy
15,411
+816
+6% +$280K 0.01% 966
2013
Q2 		$3.42M Buy
+14,595
New +$2.87M 0.01% 1471

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock Investment Management's CLDX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Celldex Therapeutics (CLDX) stake by 1.1% in Q4 2016, selling an estimated $17K and leaving 27,253 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2444.

BlackRock Investment Management first reported a position in CLDX in Q2 2013 and has held it in 15 quarters since. The position peaked at $8.83M in Q2 2015. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • BlackRock Investment Management held 27,253 shares of Celldex Therapeutics worth $1.45M as of Q4 2016.
  • BlackRock Investment Management sold 299 Celldex Therapeutics shares in Q4 2016, an estimated $17K.
  • Celldex Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2444 holding.
  • BlackRock Investment Management first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Celldex Therapeutics position peaked at $8.83M in Q2 2015.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.